Fenethylline
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Fenethylline — also known as Captagon — is a synthetic stimulant of the substituted amphetamine class. It links amphetamine to theophylline in a single molecule, designed to stimulate with less cardiovascular strain than amphetamine alone.[1] It boosts dopamine and norepinephrine while blocking adenosine receptors, producing both stimulant arousal and extended wakefulness.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized in 1961 in Germany, fenethylline was sold as Captagon and prescribed for narcolepsy, hyperkinetic disorders, and depression.[1] The WHO banned it in 1986, ending legal manufacture globally — but clandestine producers adopted the name and flooded the Arabian Peninsula with counterfeit tablets.[3][4] Most tablets sold as "Captagon" today contain no genuine fenethylline; forensic analysis finds amphetamine, caffeine, and other adulterants instead.[4]
Subjective effects include stimulation, wakefulness, cognitive euphoria, appetite suppression, and heightened focus. The experience is smoother than pure amphetamine — a steady, even alertness with less jitteriness and a prolonged wakefulness from the theophylline component. Restlessness, insomnia, and anxiety are common unsought effects; paranoia and stimulant psychosis emerge at high or chronic doses.[5]
Fenethylline carries real dependence potential driven by its amphetamine metabolite; no human death has been directly attributed to the genuine compound.[6] Cardiovascular risks at abuse doses are serious: heart attack[7] and life-threatening rhythm changes[8] have been documented. Evidence is sparse — no controlled human study has been published, and most post-2000 data come from adulterated counterfeits rather than the original compound.[4]
History[edit]
Discovery
Fenethylline was synthesized in 1961 at Degussa AG in Germany, fusing amphetamine and theophylline into a single molecule designed to stimulate with less cardiovascular strain.[1] It reached the market the same year under the brand name Captagon as a 50 mg tablet, with additional brands including Fitton and Biocapton.[1]
Clinical use and prohibition
Fenethylline was prescribed across Europe for hyperkinetic disorders, narcolepsy, and depression.[6] Brief US availability ended after reports of hallucinations and psychosis; the US placed it on Schedule I in 1981.[4] In 1986, the WHO added it to the international drug convention, ending commercial manufacture globally.[3][4]
The counterfeit Captagon trade
Beginning in the early 2000s, clandestine labs — first in southeastern Europe, then predominantly in Syria — began mass-producing counterfeit Captagon tablets.[4] Forensic analyses consistently show these tablets contain amphetamine, caffeine, or other adulterants rather than genuine fenethylline.[4][9] By 2009, an estimated 700,000 counterfeit pills were consumed daily in Saudi Arabia alone.[10]
The name Captagon became a generic term for amphetamine-type stimulants across Arabic-language media, regardless of chemical content. It gained international notoriety through coverage linking it to Syrian civil war combatants and the 2015 Paris attacks,[6] cementing its reputation as a "war drug" — though this framing oversimplifies both the pharmacology and the economics of the trade.
Chemistry[edit]
Structure
Fenethylline belongs to two chemical families simultaneously: the substituted amphetamines and the xanthines.[11] Its structure fuses a theophylline (1,3-dimethylxanthine) unit to an amphetamine unit via a two-carbon bridge — making it the only xanthine–amphetamine conjugate to have reached clinical or illicit significance. Its closest structural relatives are amphetamine and theophylline.
Molecular properties
| Molecular formula | C₁₈H₂₃N₅O₂ |
| Molecular weight | 341.4 g/mol |
The molecule carries five nitrogen atoms distributed across the purine ring system and the bridging amine.[12]
Pharmacology[edit]
Mechanism of action
The body converts fenethylline into amphetamine and theophylline, but the intact parent molecule exerts its own effects beyond what its metabolites produce.[11] The amphetamine component drives dopamine and norepinephrine release; the theophylline component blocks adenosine receptors, extending wakefulness. These two pathways act together more powerfully than either metabolite alone.[2]
Cardiovascular effects
At therapeutic doses, fenethylline raises blood pressure less than equivalent amphetamine — the theophylline relaxes blood vessels, partially offsetting the stimulant's constricting effect.[1] At abuse doses, this offset collapses: heart attack[7] and dangerous heart rhythm changes[8] have been documented.
Pharmacokinetics
No controlled human pharmacokinetic study has been published.[13] The amphetamine metabolite accounts for 23–33% of the administered dose in urine over 48 hours; theophylline accounts for approximately 14%.[12] Standard drug panels detect the amphetamine metabolite but may miss fenethylline itself — it is listed among medications that can produce amphetamine-positive test results.[14]
Neuroscience[edit]
Where it acts
The amphetamine component floods the brain's reward circuit — from the ventral tegmental area to the nucleus accumbens — with dopamine, driving euphoria and the pull toward repeated use.[2] The theophylline component lifts sleep pressure by blocking adenosine receptors, extending wakefulness beyond physiological limits.
Why it matters
The intact fenethylline molecule produces a brain signature that neither amphetamine nor theophylline alone can replicate.[15] EEG recordings in rats showed a combined pattern of cortical activation and heightened arousal that neither metabolite could reproduce separately.
Counterfeit Captagon is meaningfully worse: unlike genuine fenethylline, it suppresses BDNF — a protein that supports learning and memory — in the prefrontal cortex.[9] This suggests illicit "Captagon" may carry worse long-term cognitive consequences than the original pharmaceutical.
Does the intact fenethylline molecule bind directly to any receptor, or does its unique activity arise from the timing and ratio of metabolite release? Does theophylline's dampening of dopamine sensitization translate to lower addiction rates in humans[2]? These questions may never be answerable — prohibition and the dominance of adulterated product make controlled human studies effectively impossible.
Subjective Effects[edit]
Fenethylline produces a sustained, functional alertness — smoother and more even than pure amphetamine. The dual pharmacology layers stimulant arousal over theophylline-extended wakefulness, creating an energy curve that builds gradually and holds longer. At common doses, the experience supports focus and sociability without the sharp cardiovascular edge of pure amphetamine.
Compared to Amphetamine, fenethylline shares the core character — wakefulness, appetite suppression, and cognitive euphoria — but delivers a smoother, more prolonged ride with a milder cardiovascular signature. Compared to methamphetamine, it is less potent and shorter-acting, with a distinct addiction profile shaped by its adenosine receptor antagonism.
Effect Grid
Clear stimulation with sustained wakefulness, cognitive euphoria, and enhanced focus. Thought acceleration and motivation enhancement are noticeable. Appetite suppression is prominent. Sociability may be enhanced. The 50 mg pharmaceutical tablet — the standard clinical unit — falls squarely in this range.
Physical effects include moderate heart rate increase, dry mouth, possible muscle tension, and mild restlessness. The theophylline component provides a vasodilatory counterbalance that keeps blood pressure elevation modest relative to equivalent amphetamine doses.
Insomnia is likely if taken within 6-8 hours of intended sleep. Duration of primary effects is approximately 3-4 hours, with residual wakefulness extending beyond.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Heart rate perception changes · Insomnia · Physical fatigue · Pupil dilation · Restlessness · Dehydration sensation · Excessive sweating · Muscle tension · Body high · Bruxism · Respiratory stimulation · Dizziness · Headache · Increased urination · Nausea · Sexual arousal enhancement · Tactile euphoria · Trembling · Diarrhea · Vomiting
Restlessness · Dehydration sensation · Excessive sweating · Muscle tension · Body high · Bruxism · Respiratory stimulation · Dizziness · Headache · Increased urination · Nausea · Sexual arousal enhancement · Tactile euphoria · Trembling · Diarrhea · Vomiting
Motivation enhancement · Analysis enhancement · Information processing enhancement · Language enhancement · Thought organization · Cognitive flexibility · Pattern recognition enhancement · Creativity enhancement · Memory enhancement
Thought organization · Cognitive flexibility · Pattern recognition enhancement · Creativity enhancement · Memory enhancement
Anhedonia · Dysphoria · Emotional lability · Mania
Sociability enhancement · Social connection · Flow state
Timeline
Gradual absorption of the hydrochloride salt. Minimal perceptible effects — perhaps a faint awareness of emerging alertness as the parent compound reaches initial plasma levels.
Stimulation becomes clearly perceptible. Alertness, mild mood elevation, and the first signs of appetite suppression emerge as fenethylline reaches effective plasma concentrations.
Full stimulant effect — sustained wakefulness, cognitive euphoria, appetite suppression, enhanced focus, and cardiovascular activation. The dual amphetamine-theophylline pharmacology is maximally expressed.
Gradual decline in stimulation and euphoria. Residual wakefulness and appetite suppression persist. Irritability or restlessness may emerge as the rewarding effects fade while sympathomimetic tone remains.
Residual insomnia, possible irritability and fatigue as the amphetamine metabolite clears (t½ 10-13 hours). Theophylline clearance may be prolonged by CYP2D6 inhibition.
⚠ Avoid driving or operating machinery for at least 6 hours after dosing — residual impairment from sleep deprivation and comedown fatigue may persist beyond subjective stimulant effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · other amphetamine-type stimulants
Toxicity
No lethal dose has been established for fenethylline in any species, and no human death has been directly attributed to genuine fenethylline.[6] This reflects the scarcity of post-prohibition studies on the genuine molecule — not evidence of safety.
Heart and circulation
Fenethylline poses serious cardiovascular risks at abuse doses. A 23-year-old suffered a heart attack after captagon use, caused by coronary blood vessel spasm.[7] Two cases of reversible Brugada-pattern rhythm changes — a condition predisposing to sudden cardiac death — have been documented.[8]
Combining captagon with azithromycin (a common antibiotic) produced synergistic heart damage in rat models, including significant QT prolongation and markers of heart cell death.[16] This combination should be considered dangerous.
Neurotoxicity
Counterfeit Captagon is more neurotoxic than genuine fenethylline. It suppresses BDNF — a protein essential for learning and memory — in the prefrontal cortex, an effect not seen with the genuine compound.[9]
Psychological risks
Stimulant psychosis is the most documented psychiatric complication, and hallucinations drove fenethylline's withdrawal from the US market.[6] In a Saudi Arabian inpatient study, 25.7% of captagon users developed delusions of infidelity (morbid jealousy), associated with a 53.8% divorce rate in that group.[5] People with a personal or family history of psychotic disorders carry substantially elevated risk.[2]
Tolerance and dependence
Fenethylline produces real dependence, driven by the same dopaminergic mechanisms as amphetamine.[2] Three-quarters of drug treatment admissions in Saudi Arabia involve captagon dependence.[17]
Withdrawal symptoms — fatigue, depression, craving, and sleep disruption — are consistent with amphetamine-class discontinuation.[18] No formal withdrawal protocol exists for fenethylline.[3]
Drug interactions
The amphetamine metabolite releases serotonin, so combining fenethylline with serotonin-raising drugs — MAOIs, SSRIs, SNRIs, tramadol — risks serotonin syndrome: dangerous overheating, muscle rigidity, and cardiovascular collapse. The MAOI combination is catastrophic.safety citation needed Combining with QT-prolonging drugs — antibiotics like azithromycin, antipsychotics, or heart medications — carries synergistic heart toxicity risk.[16]
The amphetamine metabolite inhibits CYP2D6, slowing the breakdown of many other drugs.[2] Drugs with narrow safety margins that rely on CYP2D6 — certain antidepressants, codeine, tramadol, and metoprolol — may reach toxic levels. Combining with other stimulants adds cardiovascular stress and raises seizure and psychosis risk.
Contraindications
Absolute
- MAOI use (current or within 14 days): risk of catastrophic blood pressure crisis and serotonin syndromesafety citation needed
- Known Brugada syndrome: fenethylline can induce Brugada-pattern rhythm changes even in those without the condition;[8] established Brugada syndrome substantially elevates the risk of fatal rhythm disturbance
- Recent heart attack or unstable chest pain: blood vessel spasm risk documented in case report[7]
Relative
- Heart rhythm abnormalities or prolonged QT: arrhythmia risk, particularly with QT-prolonging medications[16]
- History of psychotic disorders or family history of schizophrenia: dose-dependent psychosis risk[5]
- Coronary artery disease: blood vessel spasm and accelerated artery damage[19]
- Liver impairment affecting drug metabolism: altered metabolite ratios and unpredictable effects[20]
- Concurrent use of CYP2D6-metabolized drugs with narrow safety margins: risk of toxic drug levels[2]
- Pregnancy and lactation: no fenethylline-specific safety data; amphetamine-class compounds cross the placenta and enter breast milksafety citation needed
Harm Reduction[edit]
Forms & Identification
Almost no tablet sold as "Captagon" today contains genuine fenethylline. Forensic analyses consistently find amphetamine, caffeine, and rotating adulterants including methamphetamine, procaine, and chloroquine.[4][9]
Reagent tests and dosing expectations calibrated to pharmaceutical fenethylline are unreliable for street Captagon. Quantitative laboratory analysis through a drug checking service is the only way to confirm actual contents and concentrations.
Guidelines
- Test every batch. Standard amphetamine reagent kits confirm the presence of an amphetamine-type substance but cannot distinguish genuine fenethylline from amphetamine or methamphetamine. Send a sample to a drug checking service for quantitative analysis if available.
- Start low. Street Captagon potency varies unpredictably between batches and even between tablets from the same batch.
- Do not redose within the first two hours. Onset is slow (90–120 minutes), and premature redosing is a common path to overdose-range exposure.
- Eat beforehand. Stimulants suppress appetite; starting without food increases risk of dehydration, blood sugar drops, and physical exhaustion.
- Set a hard stop. Decide in advance when the session ends. Stimulant-driven wakefulness makes it easy to extend use across days, which sharply increases psychosis and cardiovascular risk.
- Stay hydrated but do not overdrink. Sip water steadily; avoid alcohol, which masks stimulant warning signs.
Set & Setting
Fenethylline's stimulant effects are powerfully shaped by environment. A calm, familiar setting with trusted people reduces the risk of paranoia and anxious fixation that can escalate under stimulant influence. Avoid high-stress situations, confrontational social settings, or environments demanding sustained physical exertion in heat — stimulant-driven overheating is a medical emergency.
Mental state matters equally. Pre-existing anxiety, sleep deprivation, or emotional distress amplify the negative psychological trajectory of stimulant use. Open-ended stimulant use with no defined endpoint is the pattern most associated with dose escalation and psychosis.
Aftercare & integration. The stimulant comedown brings fatigue, low mood, and strong cravings. Sleep is the single most effective recovery intervention — prioritize it even if it takes time to arrive naturally. Eat calorie-dense, nutritious food as soon as appetite returns.
Allow 48–72 hours of recovery before making important decisions or assessing mood. Stimulant withdrawal depression is temporary but can feel absolute. If low mood persists beyond a week, or if paranoid thoughts linger after the drug has cleared, seek professional evaluation.
Recovery & Support
Fenethylline dependence is driven by the same dopaminergic mechanisms as amphetamine dependence, and the same treatment approaches apply. No fenethylline-specific discontinuation protocol has been published.[3]
Cognitive behavioral therapy is the best-supported intervention for amphetamine-type stimulant use disorders. Peer support groups — including SMART Recovery and 12-step programs adapted for stimulant use — provide structured accountability. If daily use has become established, medical supervision during discontinuation is advisable.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing are medical emergencies — not uncomfortable side effects. Severe paranoia with loss of contact with reality, or aggression directed at self or others, also requires immediate intervention.
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet environment if possible.
- 3. If unconscious but breathing, place in the recovery position.
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others — restraint can worsen overheating.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance (or "Captagon / amphetamine-type stimulant"), the amount taken if known, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for amphetamine-type stimulant toxicity. Hospital treatment focuses on cooling, sedation (typically benzodiazepines), and cardiac monitoring.
Legal Status[edit]
Fenethylline is prohibited in virtually every country party to the 1971 Convention on Psychotropic Substances, which added it in 1986.[3][4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Placed on Schedule I in 1981; no accepted medical use, high abuse potential[4][12] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Added by the 1986 Modification Order[21] |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Controlled substance[12] |
| International | Convention on Psychotropic Substances (1971) | Added 1986 by WHO recommendation; binding on all signatory states[3] |
| Australia | Presumed prohibited | Specific TGA schedule not confirmed; expected controlled as an amphetamine-type substancecitation needed |
| Saudi Arabia, Jordan, Syria | Illegal | Enforcement challenged by scale of counterfeit captagon production and consumption[17][22] |
Anti-doping status
Fenethylline metabolizes to amphetamine, a WADA-prohibited stimulant. Fenethylline itself is explicitly listed on the WADA Prohibited List, and use results in a positive doping test for amphetamines.[14]
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify the current law in the relevant jurisdiction before making any decisions.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcShalaby AS, Badr Nassar OM, Bahanan AO, Alshehri MH, Nasr Abou Elzahab NF (2023) Captagone & Morbid Jealousy — Psychopharmacology Bulletin PMID:36873918
- [6]